ASH Clinical Practice Guidelines on Venous Thromboembolism (VTE):
What You Should Know

The American Society of Hematology (ASH) has long recognized the need for a comprehensive set of guidelines for hematologists and other clinicians on venous thromboembolism (VTE), a common and serious blood clotting condition that includes both deep-vein thrombosis (DVT) and pulmonary embolism (PE).

In partnership with the McMaster University GRADE Centre, a world leader in guideline development and an authority on thrombosis, ASH brought together more than 100 experts including hematologists, clinicians, specialists, and patient representatives to synthesize the research and develop clinical practice guidelines for VTE.

For more information on the ASH Clinical Practice Guidelines on Venous Thromboembolism, www.hematology.org/VTEguidelines
Prophylaxis for Hospitalized and Non-Hospitalized Medical Patients

What it covers

- Who should receive an intervention and what that intervention should be
- Interventions considered include blood thinning medications of different types and mechanical compression (e.g., pneumatic compression devices or graduated compression stockings).

Why it matters

- Medical inpatients, long-term care residents, persons with minor injuries, and long-distance travelers are at increased risk of VTE, which can be fatal (20-25% of all VTE instances occur in these groups).
- It is important to ensure that at-risk patients receive the appropriate measures to prevent VTE without excess bleeding side effects.
- The guidelines recommend the best approaches for preventing VTE in these populations while minimizing unnecessary or over-treatment.

Who it affects

- Medical inpatients (including those in intensive care units), long-term care residents, persons with minor injuries, and long-distance travelers (>4 hours by air)
- Health care providers working in hospitals

What are the highlights

- For patients who are hospitalized, risk assessment for VTE and bleeding help inform a decision on effective prophylactic measures.
- In medical inpatients at high bleeding risk who require prophylaxis, mechanical prophylaxis is preferred over blood-thinning medications.
- In medical inpatients at high VTE risk but acceptable bleeding risk, blood thinning medication is preferred over mechanical prophylaxis.
- In medical inpatients, when medication is used to prevent VTE, low-molecular-weight heparin is preferred over unfractionated heparin because it is only administered once a day and has fewer complications.
- In medical inpatients, when a medication is used to prevent VTE, low-molecular-weight heparin during the hospital stay is preferred over a direct oral anticoagulant administered in hospital or after discharge.
- The use of combined modalities in medical inpatients (e.g., compression devices plus a blood thinner) is not necessary.
- Long-distance air travelers who do not have an elevated risk of thrombosis do not need to wear compression socks or take a blood thinner like aspirin to prevent thrombosis. Air travelers at substantially increased risk may benefit from graduated compression stockings or low-molecular-weight heparin.

Total number of panel recommendations: 21

REFERENCE

For more information on the ASH Clinical Practice Guidelines on Venous Thromboembolism, visit www.hematology.org/VTEguidelines

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources derived from guidelines that require updating are removed from the ASH website.

The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
Diagnosis of VTE

What it covers
- Efficient diagnostic strategies for evaluating patients with suspected VTE to provide accurate diagnosis and reduce the number of patients undergoing unnecessary and more invasive testing.

Why it matters
- Accurate diagnosis of VTE is important due to the morbidity and mortality associated with missed diagnoses and the potential side effects, patient inconvenience, and resource implications of anticoagulant treatment given for VTE.
- While a number of patients are initially suspected of having blood clots, many of them do not.
- For patients at low likelihood of having VTE, it is important to rule out VTE without subjecting patients to unnecessary tests.

Who it affects
- Patients with suspected VTE
- Clinicians and health care professionals

What are the highlights
- These recommendations confirm previous guidelines through a rigorous review of existing evidence.
- Unlike other VTE diagnosis guidelines, mathematical modelling was done to predict outcomes of various diagnostic pathways that have not been previously evaluated.
- Before considering a test, categorizing patients into the likelihood that they have VTE will help achieve an accurate diagnosis without exposing the patient to unnecessary testing.
- A D-dimer test is the best first step to check for VTE in patients with low pre-test probability; if results are negative, no further testing is required.
- When possible, clinicians should use a VQ scan, which exposes patients to lower radiation risk, versus a CT scan. Older individuals or those with preexisting lung disease are not ideal candidates for a VQ scan.

Total number of panel recommendations: 10

REFERENCE
Optimal Management of Anticoagulation Therapy

What it covers
• Optimal care management of anticoagulation therapy in patients who have previously experienced a clot

Why it matters
• Anticoagulant drugs must be used with skill in order to reduce risks of bleeding and developing another clot.
• Health care providers often have to make the difficult decision to continue or stop anticoagulation therapy following a major bleeding event.

Who it affects
• Patients who have already had a blood clot and need to take anticoagulant drugs
• Pharmacists, clinicians, nurses, and health care policy makers

What are the highlights
• Managing anticoagulation therapy is complex. Patients should receive care from specialized anticoagulation management service centers versus primary care physicians whenever possible.
• Most patients needing to interrupt warfarin for invasive procedures do not require a short-acting injectable anticoagulant administered during the peri-operative period, so-called bridge therapy.
• Management of life-threatening bleeding during anticoagulant therapy requires thoughtful use of anticoagulant reversal therapies.
• Many patients who survive major bleeding during anticoagulant therapy should resume taking anticoagulants.

Total number of panel recommendations: 25
Heparin-Induced Thrombocytopenia

What it covers
• A rare and serious adverse drug reaction that increases a patient’s risk of developing venous or arterial thromboembolism, which may be limb- or life-threatening

Why it matters
• Suspected heparin-induced thrombocytopenia (HIT) cases in hospitalized patients is the most frequently requested hematologist consult by other physicians.
• HIT can lead to amputation or death – for every day treatment is delayed, there is a ~6% risk of new thrombosis, amputation, and death.
• HIT is frequently misdiagnosed and over diagnosed.
• 12 million U.S. patients receive heparin each year, up to 1% of whom will develop HIT.

Who it affects
• Surgical patients most commonly, especially those undergoing cardiac surgery
• Hospitalists, surgeons, and cardiologists

What are the highlights
• Using a clinical scoring system, the 4Ts score, rather than a gestalt approach will improve the accuracy of diagnosis and patient outcomes.
• Treatment options include not only conventional agents such as argatroban, bivalirudin, and danaparoid, but also newer agents such as fondaparinux and the direct oral anticoagulants.

Total number of panel recommendations: 32

REFERENCE
VTE in the Context of Pregnancy

What it covers
• The diagnosis, prevention, and treatment of VTE during and after pregnancy, which are particularly challenging issues due to the need to consider fetal as well as maternal well-being

Why it matters
• Pregnancy-associated VTE is a leading cause of maternal morbidity and mortality in Western countries.
• Factors such as prior VTE, inherited clotting disorders, increasing age, cesarean delivery, co-existent diseases (e.g., sickle cell disease, lupus), and obesity also increase risk.
• Pregnant women are more likely to be older, overweight, have additional medical conditions, and undergo a cesarean delivery than in the past.

Who it affects
• Pregnant women, especially those who have previously experienced a blood clot or have other risk factors for blood clots
• Obstetrician-gynecologists, maternal fetal specialists, and internists

What are the highlights
• A conservative approach to prescribing prophylaxis, in which prophylaxis is given only to those patients for whom the available research suggests benefit, is key to minimize potential harm from over treatment.
• In the majority of cases, low-molecular-weight heparin is likely to be the best approach for managing superficial thrombosis.
• For treatment of pulmonary embolism and deep-vein thrombosis with low-molecular-weight heparin, it is acceptable to do weight-based dosing instead of using regular blood tests to adjust the dose.
• A majority of pregnant women with newly diagnosed VTE at low risk of complications can be treated as outpatients, rather than admitted to hospital, as long as the right supports are in place.

Total number of panel recommendations: 31

REFERENCE
Treatment of Pediatric VTE

What it covers
- Treating VTE in pediatric patients

Why it matters
- The incidence of VTE in children at a population level is very low, but it is higher in hospitalized children (in fact, hospital acquired VTE is said to be the second most common cause of preventable harm in hospitalized children – behind infection).
- VTE treatment and complications are different for children spanning a wide age range.
- Children are one of the most challenging patient populations to treat because VTE always occurs in the context of another serious diagnosis that also must be treated.
- Research in pediatric VTE is very limited.
- Much of the existing evidence is extrapolated from adult practice.

Who it affects
- Very ill children, newborns through 18 years of age; most common in small children and teenagers
- Pediatricians, pediatric hematologists, pediatric oncologists, pediatric intensivists, and neonatologists

What are the highlights
- Sometimes DVT causes symptoms, and sometimes it is found incidentally in an imaging study for something else. These guidelines inform how to treat these different situations. This distinction has not been addressed by guidelines in the past.
- Central venous line-associated clots are the most common clots in children.
- If the central venous line is not working and the child is at the end of treatment, it should most likely be removed.
- Renal vein thrombosis, the most common spontaneous VTE in children, should all receive anticoagulation therapy.
- Due to the low level of existing evidence, additional research is required to develop more evidence-based care recommendations.

Total number of panel recommendations: 30

REFERENCE

For more information on the ASH Clinical Practice Guidelines on Venous Thromboembolism, visit www.hematology.org/VTEguidelines

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources derived from guidelines that require updating are removed from the ASH website.

The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
Prophylaxis for Surgical Patients

What it covers
- Evidence-based research that supports decision-making to prevent venous thromboembolism (VTE) – also known as blood clots in the veins – in patients undergoing several different kinds of major surgical procedures requiring hospitalization.

Why it matters
- Before prevention measures were put into place, VTE was a common cause of death in surgery and even with such measures, blood clots can be fatal.
- Prevention of VTE is used as an important factor in assessing and measuring the quality of surgical care delivered by hospitals.
- The guidelines focus on the outcomes that are most relevant and important to patients.

Who it affects
- **Hematologists**: Along with other consultants who may be tapped to provide counsel about prevention of VTE following different types of surgery.
- **Surgeons**: Those seeking the latest information on recommended types of prevention and the timing of prevention methods.
- **Hospital Systems**: VTE prevention is a common quality benchmark for the authoritative bodies who accredit hospitals.
- **Patients**: Patients undergoing major surgical procedures requiring hospitalization after surgery to understand the risk of developing clots and the various types of prevention methods recommended for specific kinds of surgery.

What are the highlights
- Not all surgery requires measures to prevent blood clots, and the guidelines make recommendations for circumstances when the risks associated with potential bleeding may outweigh the benefits.
- The risks of blood clots associated with surgery depend on multiple factors including patient characteristics and the type of surgery. The panel made recommendations based on these factors. This includes when to consider prevention, and which type might be the most suitable – mechanical or pharmacologic.

Total number of panel recommendations: 30

REFERENCE
ASH Recommendations for Treatment of Deep Vein Thrombosis and Pulmonary Embolism

What it covers

• Evidence-based support for decision-making during each of the treatment phases of venous thromboembolism (VTE) and the recommended approach for the treatment in those phases

VTE treatment phases:

<table>
<thead>
<tr>
<th>Initial management:</th>
<th>Primary treatment:</th>
<th>Secondary prevention:</th>
</tr>
</thead>
<tbody>
<tr>
<td>from diagnosis until the first weeks of therapy</td>
<td>typically a minimum of three months</td>
<td>extends for a prolonged, usually indefinite, period of time after the primary treatment phase</td>
</tr>
</tbody>
</table>

Why it matters

• There is not a single approach to VTE treatment and prevention.
• There have been many recent clinical studies that inform/guide treatment at each of the various stages.

Who it affects

• Emergency department physicians and urgent care providers who make the initial management decisions for patients with acute deep-vein thrombosis (DVT) and pulmonary embolism (PE).
• Vascular medicine and interventional specialists who treat patients with acute, severe VTE
• Thrombosis specialists and anticoagulation providers who implement and manage the antithrombotic therapies for patients with VTE
• Hematologists who consult about risks for recurrent thrombosis and hemorrhagic complications in patients on anticoagulant therapy
• All specialists and primary care providers who diagnose and manage the chronic complications that these patients can develop, including post-thrombotic syndrome and chronic thromboembolic pulmonary hypertension

What are the highlights

• The guidelines emphasize the need for VTE treatment decisions to be patient-centric and consider patients’ perspectives that include the financial implications when choosing anti-coagulation therapy
• Strong recommendations from the panel include:
  - Use thrombolytic therapy to treat patients with pulmonary embolism who are hemodynamically compromised
  - Use anticoagulant therapy to treat patients in secondary prevention
  - Use indefinite anticoagulation therapy to treat patients with recurring VTE

• The panel also made conditional recommendations expressing a preference for home treatment over hospital-based treatment of uncomplicated cases of DVT and PE. Home treatment is suggested when there is a low risk for complications as well as a preference for direct oral anticoagulants for primary treatment of VTE.

Total number of panel recommendations: 28

REFERENCE


For more information on the ASH Clinical Practice Guidelines on Venous Thromboembolism, visit www.hematology.org/VTEguidelines

ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources derived from guidelines that require updating are removed from the ASH website.

The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
Prevention and Treatment in Patients with Cancer

What it covers
- Evidence-based recommendations for the prevention of venous thromboembolism (VTE) in patients with cancer, including those who are hospitalized, undergoing surgery, ambulatory, and/or have a central venous catheter, and for the treatment of VTE in this patient population.

Why it matters
- VTE is a common complication among patients with cancer, who account for approximately 20% of all VTE cases.
- Patients with cancer and VTE are at a markedly increased risk of recurrent VTE and early death.
- While VTE is common in this population, clinicians often do not discuss the risk with their patients.
- The occurrence of VTE in patients with cancer may interfere with planned chemotherapy regimens, worsen patient quality of life, use scarce health care resources, and increase the risk of mortality.

Who it affects
- Hematologists, oncologists, pharmacists, nurses, hospitalists, and other specialists managing care for people with cancer.
- Surgeons requiring guidance for the prevention of VTE in cancer patients undergoing surgery.
- Individuals receiving cancer treatment and/or preparing for surgery.
- Researchers seeking to address potential gaps in current guidelines.

What are the highlights
- The guidelines emphasize the importance of stratifying patients according to their underlying risk of VTE in low-, intermediate-, and high-risk groups.
- When being used in cancer patients undergoing surgery, the guidelines recommend the use of low-molecular-weight heparin (LMWH) over unfractionated heparin for the prevention of VTE.
- While other guidelines have suggested that the use of anticoagulation for the prevention of VTE in surgical patients undergoing cancer-related abdominal surgery start prior to an operation, the ASH guidelines suggest a post-operative start and make a conditional recommendation to continue prevention treatments for a month afterward.
- For ambulatory patients receiving systemic treatment who are at high risk of VTE, the ASH guidelines suggest use of oral or injectable anticoagulation treatment. However, for those ambulatory patients at low risk of VTE, use of drugs for prevention is not recommended.
- For cancer patients needing short-term treatment for VTE (initial 3 to 6 months), the guidelines recommend either LMWH or direct oral anticoagulants.
- For patients with active cancer, long-term anticoagulation (indefinite duration) is suggested to prevent recurrent VTE.

Total number of panel recommendations: 34

REFERENCE

For more information on the ASH Clinical Practice Guidelines on Venous Thromboembolism, visit www.hematology.org/VTEguidelines
ASH guidelines are reviewed annually by expert work groups convened by ASH. Resources derived from guidelines that require updating are removed from the ASH website.

The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 60 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology.
## Testing for Thrombophilia

### What it covers

- Recommendations to guide testing for hereditary and/or acquired thrombophilia (a condition characterized as a tendency to form blood clots).
- The guidelines, developed using a case-based approach and modeling, are founded on three potential treatment decisions based on the outcome of testing:
  - Whether to continue or discontinue treatment for secondary prevention of VTE.
  - Whether to provide anticoagulant prophylaxis for prevention of VTE in patients with risk factors.
  - Whether to avoid hormonal treatments, such as oral contraceptive pills (OCP) or hormone replacement therapy (HRT).

### Why it matters

- Hereditary and acquired thrombophilia are blood coagulation disorders that increase the risk for venous thromboembolism (VTE) and affect approximately 10% of the population.
- Thrombophilia testing is costly and whether testing helps in guiding treatment decisions is controversial.
- However, lifelong anticoagulation is expensive as well, and testing to withhold treatment might be cost effective.

### Who it affects

- Clinicians and health care professionals including hematologists, internists, primary care physicians, obstetricians and gynecologists, clinical laboratory physicians, and emergency care physicians.
- Patients with VTE and individuals with a family history of thrombophilia and/or VTE.
- Women considering using combined oral contraceptives or hormone replacement therapy, women who are planning pregnancy, and patients with cancer who are classified to be at low or moderate risk of VTE.

### What are the highlights

- The ASH panel suggests limiting testing for thrombophilia to specific situations:
  - Patients with VTE provoked by non-surgical risk factors, including pregnancy, postpartum, or use of oral contraceptives.
  - Patients with VTE at unusual sites within the body, if the standard of care is to treat patients for three to six months.
  - Individuals with a family history of VTE and high-risk thrombophilia (antithrombin, protein C, or protein S deficiency) in order to determine if pharmacological thrombosis prophylaxis during transient thrombosis risk factors is necessary.
  - Women with a family history of VTE and high-risk thrombophilia (antithrombin, protein C, or protein S deficiency), in order to determine if postpartum and/or antepartum prophylaxis is necessary.
  - Ambulatory cancer patients with a family history of VTE and who are otherwise at low or intermediate risk for VTE, to guide decisions on use of pharmacological thromboprophylaxis.
  - Women with a family history of VTE and high-risk thrombophilia (antithrombin, protein C, or protein S deficiency), in order to avoid use of hormone treatments, such as birth control pills.
  - In all other instances, the panel suggests not testing for thrombophilia.
  - Nearly all recommendations are based on very low certainty in the evidence resulting in only one strong recommendation (against testing the general population before starting combined oral contraceptives).

### Total number of panel recommendations: 23

**REFERENCE**